ES2624605T3 - IL-6 y receptor de IL-6 humanizados - Google Patents
IL-6 y receptor de IL-6 humanizados Download PDFInfo
- Publication number
- ES2624605T3 ES2624605T3 ES14177863.9T ES14177863T ES2624605T3 ES 2624605 T3 ES2624605 T3 ES 2624605T3 ES 14177863 T ES14177863 T ES 14177863T ES 2624605 T3 ES2624605 T3 ES 2624605T3
- Authority
- ES
- Spain
- Prior art keywords
- human
- murine
- gene
- mouse
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 43
- 102000004889 Interleukin-6 Human genes 0.000 title claims abstract description 42
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title description 38
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title description 34
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 129
- 102000052611 human IL6 Human genes 0.000 claims abstract description 124
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 102
- 241001529936 Murinae Species 0.000 claims abstract description 92
- 230000001105 regulatory effect Effects 0.000 claims abstract description 32
- 210000001185 bone marrow Anatomy 0.000 claims description 27
- 101100286713 Homo sapiens IL6 gene Proteins 0.000 claims description 22
- 108700024394 Exon Proteins 0.000 claims description 17
- 206010035485 plasmacytosis Diseases 0.000 claims description 17
- 210000000952 spleen Anatomy 0.000 claims description 17
- 210000003593 megakaryocyte Anatomy 0.000 claims description 16
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 10
- 210000001165 lymph node Anatomy 0.000 claims description 10
- 210000004180 plasmocyte Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 8
- 206010041660 Splenomegaly Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 230000002547 anomalous effect Effects 0.000 claims description 6
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 190
- 241000699670 Mus sp. Species 0.000 description 134
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 110
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 52
- 210000003719 b-lymphocyte Anatomy 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 34
- 238000011830 transgenic mouse model Methods 0.000 description 32
- 241000699660 Mus musculus Species 0.000 description 31
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 25
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 22
- 206010048998 Acute phase reaction Diseases 0.000 description 21
- 230000004658 acute-phase response Effects 0.000 description 21
- 210000001671 embryonic stem cell Anatomy 0.000 description 20
- 229940100601 interleukin-6 Drugs 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 101100286719 Mus musculus Il6 gene Proteins 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 238000011529 RT qPCR Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000003393 splenic effect Effects 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 8
- 102100022338 Integrin alpha-M Human genes 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 230000007342 reactive astrogliosis Effects 0.000 description 8
- 108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 101150047862 hil-6 gene Proteins 0.000 description 7
- 238000011577 humanized mouse model Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000004885 white matter Anatomy 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 6
- 102100027584 Protein c-Fos Human genes 0.000 description 6
- 102100038081 Signal transducer CD24 Human genes 0.000 description 6
- 241000779819 Syncarpia glomulifera Species 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000002025 microglial effect Effects 0.000 description 6
- 239000001739 pinus spp. Substances 0.000 description 6
- 229940036248 turpentine Drugs 0.000 description 6
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 5
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 5
- 101150101999 IL6 gene Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101150090318 Hil gene Proteins 0.000 description 4
- 101100452395 Mus musculus Il6ra gene Proteins 0.000 description 4
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004225 Cathepsin B Human genes 0.000 description 3
- 108090000712 Cathepsin B Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000003297 immature b lymphocyte Anatomy 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 230000007171 neuropathology Effects 0.000 description 3
- 201000008752 progressive muscular atrophy Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 101150012195 PREB gene Proteins 0.000 description 2
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 101150084279 TM gene Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 2
- 210000001056 activated astrocyte Anatomy 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 238000011714 129 mouse Methods 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAXโข mouse strain) Methods 0.000 description 1
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010061005 Cardiac myxoma Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100452394 Homo sapiens IL6R gene Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108020004509 Intracisternal A-Particle Genes Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 206010073599 Myeloma cast nephropathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 108091027569 Z-DNA Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 doseโresponse relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000004667 early pro-b cell Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000014 large pre-b cell Anatomy 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000345 small pre-b cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552900P | 2011-10-28 | 2011-10-28 | |
| US201161552900P | 2011-10-28 | ||
| US201161556579P | 2011-11-07 | 2011-11-07 | |
| US201161556579P | 2011-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2624605T3 true ES2624605T3 (es) | 2017-07-17 |
Family
ID=47295138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14177863.9T Active ES2624605T3 (es) | 2011-10-28 | 2012-10-29 | IL-6 y receptor de IL-6 humanizados |
| ES12795905.4T Active ES2525368T3 (es) | 2011-10-28 | 2012-10-29 | IL-6 y receptor de IL-6 humanizados |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12795905.4T Active ES2525368T3 (es) | 2011-10-28 | 2012-10-29 | IL-6 y receptor de IL-6 humanizados |
Country Status (27)
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizaรงรตes dos mesmos |
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| US20130261016A1 (en) * | 2012-03-28 | 2013-10-03 | Meso Scale Technologies, Llc | Diagnostic methods for inflammatory disorders |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| KR102241962B1 (ko) | 2012-09-07 | 2021-04-20 | ์์ผ ์ ๋๋ฒ์ํฐ | ์ ์ ์ ์ผ๋ก ๋ณํ๋ ๋น-์ธ๊ฐ ๋๋ฌผ ๋ฐ ์ด๊ฒ๋ค์ ์ฌ์ฉ ๋ฐฉ๋ฒ |
| EP2896291B1 (en) * | 2012-09-13 | 2019-03-20 | Chugai Seiyaku Kabushiki Kaisha | Gene knock-in non-human animal |
| DK4389764T3 (da) * | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmรฅder til anvendelse heraf |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miลก, ki izraลพa humanizirani poglavitni histokompatibilnostni kompleks |
| GB2513884B (en) | 2013-05-08 | 2015-06-17 | Univ Bristol | Method and apparatus for producing an acoustic field |
| HRP20231121T1 (hr) * | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | ลฝivotinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| JP6492095B2 (ja) * | 2013-10-15 | 2019-03-27 | ใชใธใงใใญใณใปใใกใผใใทใฅใผใใฃใซใซใบใปใคใณใณใผใใฌใคใใใ๏ผฒ๏ฝ ๏ฝ๏ฝ ๏ฝ๏ฝ ๏ฝ๏ฝ๏ฝ ๏ผฐ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ผ ๏ผฉ๏ฝ๏ฝ๏ผ | ใใๅ๏ฝ๏ฝโ๏ผ๏ผๅ็ฉ |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| US20150143559A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| US9612658B2 (en) | 2014-01-07 | 2017-04-04 | Ultrahaptics Ip Ltd | Method and apparatus for providing tactile sensations |
| CA2934965A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| RS60398B1 (sr) | 2014-04-08 | 2020-07-31 | Regeneron Pharma | Ne-humane ลพivotinje sa humanizovanim fc-gama receptorima |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (cg-RX-API-DMAC10.html) | 2014-05-07 | 2018-08-04 | ||
| EP3482629B1 (en) | 2014-05-19 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human epo |
| ES2691529T3 (es) | 2014-05-30 | 2018-11-27 | Regeneron Pharmaceuticals, Inc. | Animales con dipeptidil peptidasa iv (dpp4) humanizada |
| WO2015196051A1 (en) * | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| GB2530036A (en) | 2014-09-09 | 2016-03-16 | Ultrahaptics Ltd | Method and apparatus for modulating haptic feedback |
| BR112017010793A2 (pt) | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal nรฃo humano geneticamente modificado, camundongo, mรฉtodos para produzir um animal nรฃo humano geneticamente modificado e de triagem de candidatos a fรกrmaco direcionados a um antรญgeno de interesse, e, modelo de camundongo. |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptรญdeo cd47, cรฉlula ou tecido de roedor isolado, cรฉlula-tronco emprionรกria de roedor, embriรฃo de roedor, e, mรฉtodos de produzir um roedor, de fornecimento de um roedor, de enxerto de cรฉlulas humanas em um roedor, de avaliaรงรฃo de eficรกcia terapรชutica de uma droga direcionada a cรฉlulas humanas e de avaliar as propriedades farmacocinรฉticas, de avaliar a toxicidade especรญfica e inespecรญfica de uma droga direcionada ao cd47 humano. |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciaciรณn 274 humanizado |
| KR102524966B1 (ko) | 2015-02-20 | 2023-04-21 | ์ธํธ๋ผํ ํฑ์ค ์์ดํผ ์ํฐ๋ | ํ ํฑ ์์คํ ์์์ ์๊ณ ๋ฆฌ์ฆ ๊ฐ์ |
| EP3537265B1 (en) | 2015-02-20 | 2021-09-29 | Ultrahaptics Ip Ltd | Perceptions in a haptic system |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por cรฉlulas t humanizadas en animales no humanos. |
| ES2950399T3 (es) | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y mรฉtodos de uso de los mismos |
| US10818162B2 (en) | 2015-07-16 | 2020-10-27 | Ultrahaptics Ip Ltd | Calibration techniques in haptic systems |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | ็ๆณฝๆฉๅถ่ฏๅ ฌๅธ | ๅ ทๆไบบๆบๅๆทๅทด็ป่ๆดปๅๅบๅ 3็้ไบบๅจ็ฉ |
| MY207684A (en) | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| US11189140B2 (en) | 2016-01-05 | 2021-11-30 | Ultrahaptics Ip Ltd | Calibration and detection techniques in haptic systems |
| WO2017136712A1 (en) | 2016-02-04 | 2017-08-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | ๅ็ๅ ๅถ่ฏๅ ฌๅธ | ๅ ทๆไบบๆบๅ็tmprssๅบๅ ็ๅฎ้ฝฟ็ฑปๅจ็ฉ |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | ็ๆณฝๆฉๅถ่ฏๅ ฌๅธ | ่กจ่พพๅคๆบๆซ็ซฏ่ฑๆฐงๆ ธ่ท้ ธ่ฝฌ็งป้ ถ็้ไบบๅจ็ฉ |
| US10531212B2 (en) | 2016-06-17 | 2020-01-07 | Ultrahaptics Ip Ltd. | Acoustic transducers in haptic systems |
| US10268275B2 (en) | 2016-08-03 | 2019-04-23 | Ultrahaptics Ip Ltd | Three-dimensional perceptions in haptic systems |
| US10755538B2 (en) | 2016-08-09 | 2020-08-25 | Ultrahaptics ilP LTD | Metamaterials and acoustic lenses in haptic systems |
| CN107815467B (zh) | 2016-08-31 | 2021-03-16 | ็พๅฅฅ่ตๅพ(ๅไบฌ)ๅป่ฏ็งๆ่กไปฝๆ้ๅ ฌๅธ | ไบบๆบๅๅบๅ ๆน้ ๅจ็ฉๆจกๅ็ๅถๅคๆนๆณๅๅบ็จ |
| US10943578B2 (en) | 2016-12-13 | 2021-03-09 | Ultrahaptics Ip Ltd | Driving techniques for phased-array systems |
| US10497358B2 (en) | 2016-12-23 | 2019-12-03 | Ultrahaptics Ip Ltd | Transducer driver |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | ็พๅฅฅ่ตๅพๆฑ่ๅบๅ ็็ฉๆๆฏๆ้ๅ ฌๅธ | ไธ็งcd132ๅบๅ ็ผบๅคฑ็ๅ ็ซ็ผบ้ทๅจ็ฉๆจกๅ็ๅถๅคๆนๆณๅๅบ็จ |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPฮฑ |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | ๅไบฌ็พๅฅฅ่ตๅพๅบๅ ็็ฉๆๆฏๆ้ๅ ฌๅธ | Cd47ๅบๅ ไบบๆบๅๆน้ ๅจ็ฉๆจกๅ็ๅถๅคๆนๆณๅๅบ็จ |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| US11531395B2 (en) | 2017-11-26 | 2022-12-20 | Ultrahaptics Ip Ltd | Haptic effects from focused acoustic fields |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | ใชใธใงใใญใณใปใใกใผใใทใฅใผใใฃใซใซใบใปใคใณใณใผใใฌใคใใใ | ใใๅ๏ฝ๏ฝ๏ฝ๏ฝ้บไผๅญๅบงใๅซใ้ใใๅ็ฉ |
| JP7483610B2 (ja) | 2017-12-22 | 2024-05-15 | ใฆใซใใฉใใใใฃใฏใน ใขใคใใผ ใชใใใใ | ่งฆ่ฆใทในใใ ใซใใใไธ่ฆใชๅฟ็ญใฎๆๅฐๅ |
| US11360546B2 (en) | 2017-12-22 | 2022-06-14 | Ultrahaptics Ip Ltd | Tracking in haptic systems |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| AU2019264014A1 (en) | 2018-05-02 | 2020-12-03 | Ultrahaptics Ip Ltd | Blocking plate structure for improved acoustic transmission efficiency |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| US11098951B2 (en) | 2018-09-09 | 2021-08-24 | Ultrahaptics Ip Ltd | Ultrasonic-assisted liquid manipulation |
| US11378997B2 (en) | 2018-10-12 | 2022-07-05 | Ultrahaptics Ip Ltd | Variable phase and frequency pulse-width modulation technique |
| US20220015343A1 (en) * | 2018-12-17 | 2022-01-20 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| WO2020141330A2 (en) | 2019-01-04 | 2020-07-09 | Ultrahaptics Ip Ltd | Mid-air haptic textures |
| US12373033B2 (en) | 2019-01-04 | 2025-07-29 | Ultrahaptics Ip Ltd | Mid-air haptic textures |
| WO2020147829A1 (zh) * | 2019-01-17 | 2020-07-23 | ๅไบฌ็พๅฅฅ่ตๅพๅบๅ ็็ฉๆๆฏๆ้ๅ ฌๅธ | ไบบๆบๅ่ฝฌๅบๅ ๅจ็ฉ |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | ใชใธใงใใญใณใปใใกใผใใทใฅใผใใฃใซใซใบใปใคใณใณใผใใฌใคใใใ | ใใๅๅๅบๅ ๅญ๏ผ๏ผ้บไผๅญๅบงใๅซใ้ใใๅ็ฉ |
| US11842517B2 (en) | 2019-04-12 | 2023-12-12 | Ultrahaptics Ip Ltd | Using iterative 3D-model fitting for domain adaptation of a hand-pose-estimation neural network |
| EP3978607B1 (en) | 2019-05-27 | 2025-08-20 | Transgenic Inc. | Exon-humanized mouse |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | ็ๆณฝๆฉๅถ่ฏๅ ฌๅธ | ๅ ๆฌไบบๆบๅ็ฝ่็ฝๅบๅ ๅบง็้ไบบๅจ็ฉ |
| US11374586B2 (en) | 2019-10-13 | 2022-06-28 | Ultraleap Limited | Reducing harmonic distortion by dithering |
| CN114631139A (zh) | 2019-10-13 | 2022-06-14 | ่ถ ้ฃ่ทๆ้ๅ ฌๅธ | ๅฉ็จ่ๆ้บฆๅ ้ฃ่ฟ่กๅจๆๅฐ้กถ |
| WO2021090028A1 (en) | 2019-11-08 | 2021-05-14 | Ultraleap Limited | Tracking techniques in haptics systems |
| CN111304246B (zh) * | 2019-12-17 | 2021-05-04 | ็พๅฅฅ่ตๅพๆฑ่ๅบๅ ็็ฉๆๆฏๆ้ๅ ฌๅธ | ไธ็งไบบๆบๅ็ป่ๅ ๅญๅจ็ฉๆจกๅใๅถๅคๆนๆณๅๅบ็จ |
| US11715453B2 (en) | 2019-12-25 | 2023-08-01 | Ultraleap Limited | Acoustic transducer structures |
| WO2021154791A1 (en) * | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| KR20230004472A (ko) | 2020-04-21 | 2023-01-06 | ๋ฆฌ์ ๋๋ก ํ๋ง์ํฐ์นผ์ค ์ธ์ฝํฌ๋ ์ดํฐ๋ | ์ธ๊ฐํ cxcl13 ์ ์ ์๋ฅผ ๊ฐ๋ ๋น์ธ๊ฐ ๋๋ฌผ |
| US11816267B2 (en) | 2020-06-23 | 2023-11-14 | Ultraleap Limited | Features of airborne ultrasonic fields |
| US11886639B2 (en) | 2020-09-17 | 2024-01-30 | Ultraleap Limited | Ultrahapticons |
| CN116981357A (zh) | 2021-03-31 | 2023-10-31 | ็ๆณฝๆฉๅถ่ฏๅ ฌๅธ | ๅ ๅซๅ ทๆๆนๅ็tcrb็ปๅบๅคๆ ทๆง็ไบบๆบๅ็ป่ๅ ็ซ็ณป็ป็ปๅ็ๅบๅ ไฟฎ้ฅฐ็ๅฐ้ผ |
| US12517585B2 (en) | 2021-07-15 | 2026-01-06 | Ultraleap Limited | Control point manipulation techniques in haptic systems |
| US12688761B2 (en) | 2022-01-02 | 2026-07-21 | Sim Ip Hxr Llc | Mid-air haptic generation analytic techniques |
| EP4593590A1 (en) | 2022-09-29 | 2025-08-06 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| US12659636B2 (en) | 2022-10-11 | 2026-06-16 | Sim Ip Hxr Llc | Acoustic transducer mounts |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2202549C (en) * | 1994-10-14 | 2003-08-05 | Tara Seshadri | Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene |
| PL182089B1 (en) | 1994-10-21 | 2001-11-30 | Chugai Pharmaceutical Co Ltd | Pharmaceutic compositions for treating diseases caused by production of il-6 |
| US20030082721A1 (en) * | 2001-01-17 | 2003-05-01 | Tai-Jay Chang | Transgenic animals expressing androgen receptor complex-associated protein |
| CN1560081A (zh) * | 2004-02-17 | 2005-01-05 | ๅคง่ฟๅธๆฉ็็ฉๅทฅ็จๆ้ๅ ฌๅธ | ็จ่ฝไบง็ไบบIgGl้้พ๏ผฮบ่ฝป้พๅฐ้ผ ไฝไธบๅถๅคไบบๆบๅๅๅ ้ๆไฝๅๅบ็จ |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| US7759541B2 (en) * | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikรถrper gegen den humanen il-6- rezeptor |
| EP2064325B1 (en) * | 2006-09-01 | 2011-12-07 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| FR2942218A1 (fr) | 2009-02-13 | 2010-08-20 | Eurocave Sa | Appareil de service au verre d'un liquide, notamment de vin |
| EP4502152A3 (en) * | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| EP3498730B1 (en) * | 2009-12-21 | 2026-01-28 | Regeneron Pharmaceuticals, Inc. | Humanized fc gamma r mice |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizaรงรตes dos mesmos |
| KR102366029B1 (ko) | 2011-09-30 | 2022-02-23 | ์ถ๊ฐ์ด ์ธ์ด์ผ์ฟ ๊ฐ๋ถ์ํค๊ฐ์ด์ค | ํ์ ํญ์์ ๋ํ ๋ฉด์ญ์๋ต์ ์ ๋ํ๋ ํญ์ ๊ฒฐํฉ ๋ถ์ |
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miลกevi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | ๋ฆฌ์ ๋๋ก ํ์๋ง์ํฐ์ปฌ์ค, ์ธํฌ. | ์ ์ ์ ๋ณํ๋ ์ฃผ์ ์กฐ์ง์ ํฉ์ฑ ๋ณตํฉ์ฒด ๋ง์ฐ์ค |
-
2012
- 2012-10-29 SI SI201230941A patent/SI2818478T1/sl unknown
- 2012-10-29 RU RU2017129763A patent/RU2751240C2/ru active
- 2012-10-29 PL PL12795905T patent/PL2663575T3/pl unknown
- 2012-10-29 IN IN3920CHN2014 patent/IN2014CN03920A/en unknown
- 2012-10-29 CN CN201280065013.6A patent/CN104039821A/zh active Pending
- 2012-10-29 CN CN201810620759.8A patent/CN108866101A/zh active Pending
- 2012-10-29 RU RU2014121324A patent/RU2634417C2/ru active
- 2012-10-29 HR HRP20141192AT patent/HRP20141192T1/hr unknown
- 2012-10-29 DK DK14177863.9T patent/DK2818478T3/en active
- 2012-10-29 SG SG10202100485XA patent/SG10202100485XA/en unknown
- 2012-10-29 BR BR112014008529A patent/BR112014008529A2/pt not_active Application Discontinuation
- 2012-10-29 EP EP12795905.4A patent/EP2663575B1/en active Active
- 2012-10-29 WO PCT/US2012/062379 patent/WO2013063556A1/en not_active Ceased
- 2012-10-29 PL PL14177863T patent/PL2818478T3/pl unknown
- 2012-10-29 KR KR1020207005686A patent/KR102234632B1/ko active Active
- 2012-10-29 ES ES14177863.9T patent/ES2624605T3/es active Active
- 2012-10-29 LT LTEP14177863.9T patent/LT2818478T/lt unknown
- 2012-10-29 SI SI201230111T patent/SI2663575T1/sl unknown
- 2012-10-29 US US13/662,880 patent/US8878001B2/en active Active
- 2012-10-29 SM SM20170222T patent/SMT201700222T1/it unknown
- 2012-10-29 MY MYPI2017703646A patent/MY186903A/en unknown
- 2012-10-29 JP JP2014539105A patent/JP6120451B2/ja active Active
- 2012-10-29 RS RS20170430A patent/RS55949B1/sr unknown
- 2012-10-29 PT PT127959054T patent/PT2663575E/pt unknown
- 2012-10-29 MY MYPI2014000768A patent/MY172726A/en unknown
- 2012-10-29 KR KR1020147014316A patent/KR102084927B1/ko active Active
- 2012-10-29 HU HUE14177863A patent/HUE033400T2/en unknown
- 2012-10-29 ES ES12795905.4T patent/ES2525368T3/es active Active
- 2012-10-29 RS RS20140677A patent/RS53683B1/sr unknown
- 2012-10-29 PT PT141778639T patent/PT2818478T/pt unknown
- 2012-10-29 CA CA2853731A patent/CA2853731C/en active Active
- 2012-10-29 SG SG10201600965YA patent/SG10201600965YA/en unknown
- 2012-10-29 MX MX2014004900A patent/MX358390B/es active IP Right Grant
- 2012-10-29 EP EP14177863.9A patent/EP2818478B1/en active Active
- 2012-10-29 SG SG11201400945UA patent/SG11201400945UA/en unknown
- 2012-10-29 DK DK12795905.4T patent/DK2663575T3/en active
-
2014
- 2014-04-03 IL IL231896A patent/IL231896B/en active IP Right Grant
- 2014-04-10 ZA ZA2014/02635A patent/ZA201402635B/en unknown
- 2014-09-19 US US14/490,877 patent/US9078418B2/en active Active
- 2014-09-19 US US14/490,875 patent/US9125386B2/en active Active
- 2014-12-11 CY CY20141101035T patent/CY1116614T1/el unknown
- 2014-12-15 SM SM201400187T patent/SMT201400187B/xx unknown
-
2015
- 2015-06-10 US US14/735,710 patent/US9392777B2/en active Active
- 2015-07-30 AU AU2015207889A patent/AU2015207889B2/en active Active
-
2016
- 2016-01-18 IL IL243665A patent/IL243665B/en active IP Right Grant
- 2016-01-18 IL IL243666A patent/IL243666B/en active IP Right Grant
- 2016-06-09 US US15/177,582 patent/US9622460B2/en active Active
- 2016-11-14 US US15/350,739 patent/US10004211B2/en active Active
- 2016-11-18 JP JP2016224713A patent/JP2017035115A/ja active Pending
-
2017
- 2017-04-28 HR HRP20170656TT patent/HRP20170656T1/hr unknown
- 2017-04-28 CY CY20171100474T patent/CY1118952T1/el unknown
-
2018
- 2018-06-06 US US16/001,074 patent/US10433528B2/en active Active
-
2019
- 2019-01-28 IL IL264508A patent/IL264508B/en active IP Right Grant
- 2019-07-03 US US16/502,197 patent/US11102962B2/en active Active
-
2021
- 2021-07-26 US US17/385,039 patent/US12239111B2/en active Active
-
2025
- 2025-01-29 US US19/039,847 patent/US20250287931A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250287931A1 (en) | Humanized il-6 and il-6 receptor | |
| AU2012327206B2 (en) | Humanized IL-6 and IL-6 receptor | |
| HK1205135B (en) | Humanized il-6 and il-6 receptor | |
| HK1190408B (en) | Humanized il-6 and il-6 receptor | |
| NZ709432B2 (en) | Humanized il-6 and il-6 receptor | |
| NZ623145B2 (en) | Humanized il-6 and il-6 receptor |